Amalgamated Bank’s Tourmaline Bio TRML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-567
| Closed | -$27K | – | 3004 |
|
|
2025
Q3 | $27K | Sell |
567
-232
| -29% | -$6.43K | ﹤0.01% | 2015 |
|
|
2025
Q2 | $13K | Hold |
799
| – | – | ﹤0.01% | 2332 |
|
|
2025
Q1 | $12K | Hold |
799
| – | – | ﹤0.01% | 2301 |
|
|
2024
Q4 | $16K | Hold |
799
| – | – | ﹤0.01% | 2221 |
|
|
2024
Q3 | $21K | Hold |
799
| – | – | ﹤0.01% | 2121 |
|
|
2024
Q2 | $10K | Buy |
+799
| New | +$12.9K | ﹤0.01% | 2471 |
|
|
2023
Q2 | – | Sell |
-231
| Closed | -$4K | – | 3121 |
|
|
2023
Q1 | $4K | Sell |
231
-48
| -17% | -$792 | ﹤0.01% | 2914 |
|
|
2022
Q4 | $3K | Hold |
279
| – | – | ﹤0.01% | 2957 |
|
|
2022
Q3 | $7K | Hold |
279
| – | – | ﹤0.01% | 2977 |
|
|
2022
Q2 | $13K | Sell |
279
-39
| -12% | -$3.08K | ﹤0.01% | 2952 |
|
|
2022
Q1 | $31K | Buy |
+318
| New | +$29.8K | ﹤0.01% | 2665 |
|
Amalgamated Bank's TRML Position: Q4 2025 in Review
Amalgamated Bank sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 567 shares — an estimated $27K sold.
Amalgamated Bank first reported a position in TRML in Q1 2022 and held it in 11 quarters. The position peaked at $31K in Q1 2022. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.
- Amalgamated Bank reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
- Amalgamated Bank sold 567 Tourmaline Bio shares in Q4 2025, an estimated $27K.
- Amalgamated Bank first reported a position in Tourmaline Bio in Q1 2022 and held it in 11 quarters.
- Amalgamated Bank's Tourmaline Bio position peaked at $31K in Q1 2022.
- 0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.
Based on Amalgamated Bank's 13F filing for Q4 2025, filed 5 Feb 2026.